Business Context and Reporting Period
This Form 6-K filing by Psyence Biomedical Ltd. covers the month of August 2024, specifically reporting on a material agreement entered into on August 15, 2024. The document details a first addendum to a Securities Purchase Agreement dated January 15, 2024, involving the holders of the Company's senior convertible notes.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or total debt levels. The financial data present relates exclusively to the terms of the new agreement:
- Conversion Floor: A floor of $0.50 per share applies to the conversion price for specific tranches of notes.
- Issuance Consideration: The Company agreed to issue 1,000,000 common shares and warrants to purchase 500,000 common shares (exercise price $0.50) to note holders.
- Future Fees: A cash fee equal to 50% of aggregate gross proceeds from future offerings is payable to holders until $655,625.00 is paid. Up to 50% of this fee may be paid in shares at $0.50 per share under specific conditions.
Material Changes
The primary material change is the restructuring of the relationship with senior convertible note holders through the Addendum:
- Debt Conversion: Holders are required to convert all outstanding convertible promissory notes at the applicable conversion price.
- Waivers: Holders waived rights to call an event of default regarding certain deficiencies and abandoned related claims.
- Liquidity Restrictions Lifted: The Company is no longer restricted from issuing securities under its existing equity line of credit with White Lion Capital, LLC, or issuing common shares at prices no less than $0.50 per share.
- Registration Rights: Restrictions on registering shares issued under the White Lion Purchase Agreement or future issuances at $0.50 or higher have been removed.
- Lock-up Releases: Holders consented to the release from lock-up of 500,000 common shares held by the Parent company immediately, and an additional 500,000 shares five days following the note conversion.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or management commentary on future business strategy. However, it highlights specific contingencies and risks associated with the agreement:
- Effectiveness Condition: The Addendum becomes effective only upon the issuance of certain securities to holders by no later than August 27, 2024.
- Future Offering Costs: The Company faces a significant cost of capital for future fundraising, as 50% of gross proceeds will be directed to note holders until the $655,625 threshold is met.
- Dilution: The agreement mandates the immediate issuance of 1,000,000 shares and 500,000 warrants, alongside potential future share issuances for fees.
Investor Verification Checklist
- Verify the successful issuance of securities to note holders by the August 27, 2024 deadline to confirm the Addendum's effectiveness.
- Confirm the exact number of shares issued for the 1,000,000 share consideration and the 500,000 warrant grant.
- Monitor future capital raising activities to assess the impact of the 50% gross proceeds fee on net capital raised.
- Check the status of the lock-up release for the 1,000,000 shares held by Psyence Group Inc. (Parent).
- Review the updated terms of the White Lion Capital equity line of credit to confirm the removal of issuance restrictions.